Nivolumab + CRT Improves DFS in High-Risk Locally Advanced HNSCC in NIVOPOSTOP Trial

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the NIVOPOSTOP trial, which assessed adjuvant nivolumab added to chemoradiotherapy in patients with resected head and neck squamous cell carcinoma. This abstract will be presented as LBA2 during the Plenary Session at the 2025 ASCO Annual Meeting. Read the full abstract: https://meetings.asco.org/abstracts-presentations/245968 For more on ASCO25, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 19, 2025_

Video Lainnya